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Ex vivo IL-12 priming of tumor-reactive CD8+ T-cells
enhances their persistence and subsequent anti-tumor
efficacy upon adoptive cell transfer (ACT) into lymphode-
pleted mice. Since IL-7 and IL-15 are considered critical
for the persistence of adoptively transferred T-cells, we
investigated the responsiveness of IL-12 primed CD8+
T-cells to these homeostatic cytokines to help elucidate
the mechanisms behind their superior anti-tumor abilities.
Using pmel-1 T-cell receptor transgenic mice, we found
that pmel CD8+ T cells activated in the presence of IL-12
(pmelIL-12) showed much greater expansion in an irra-
diated (6 Gy) host compared to cells activated without
IL-12 (pmelsham). This expansion was dependent on host
IL-7, but not IL-15. Compared to pmelsham, pmelIL-12
demonstrated greatly enhanced in vitro IL-7 responsive-
ness, as measured by proliferation and phosphorylation of
signaling molecules STAT5, S6 and AKT. These striking
differences were not seen with IL-15. Despite not playing
a major role in pmelIL-12 effector phase expansion, IL-15
was critical for maximum anti-tumor efficacy of pmelIL-
12, as irradiated mice devoid of IL-15, like mice receiving
IL-7 neutralizing antibody (clone M25), showed reduced
survival compared to irradiated mice receiving pmelIL-12
only. This decreased tumor control likely occurred because
IL-15 was needed for long-term persistence of pmelIL-12.
Together, these findings suggest that IL-12 priming of CD8
+ T-cells augments the efficacy of ACT protocols in part
by conferring an enhanced ability to respond to IL-7,
thereby enabling transferred cells to persist in the IL-7 rich
post-lymphodepletion environment.
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